100% efficacy for HIV prevention.

That’s what the results from the PURPOSE 1 clinical trial showed. For her role in shaping studies around the first HIV drug to offer long-lasting protection, Moupali Das was a recipient of this year’s AAAS Mani L. Bhaumik Breakthrough of the Year Award.

Lenacapavir has been approved by the FDA, a milestone in the fight to end HIV. Moupali Das & Yvette Raphael ensured those who would most benefit from the drug were included in clinical trials. They received the AAAS Bhaumik Breakthrough of the Year award for their roles in the drug’s development.

A Federal Lab That Tracked Rising S.T.I.s Has Been Shuttered (Gift Article) The United States can no longer keep tabs on drug-resistant gonorrhea, among other infections, scientists said.

Drug-resistant gonorrhea, a form of the widespread sexually transmitted infection, is considered an urgent health threat worldwide. The US has just lost its ability to detect it.

www.nytimes.com/2025/04/04/h...

Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater ...

Promising signs for ‘one jab a year’ PrEP.
We don’t have a vaccine to protect against HIV - but this is as good!
www.aidsmap.com/news/mar-202...

Gilead's Once-Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention

Dr. Moupali Das from Gilead Sciences presented their Phase 1 results on once-yearly intramuscular lenacapavir for #HIVprevention.

Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 #IDsky #MEDsky #HIVsky

www.contagionlive.com/view/gilead-...

HIV Prevention: Discussing PrEP, PEP, and Vaccine Development Colleen Kelley, MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vacci...

Colleen Kelley MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vaccine development. #CROI #croi2025
#IDsky #IDMed

ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV Suppression Anchalee Avihingsanon, MD, PhD presents results showing 95.4% HIV RNA suppression and 86.6% HBV DNA suppression after 48 weeks of B/F/TAF in HIV-HBV co-infected patients.

Dr. Avihingsanon, Principal Investigator of the ALLIANCE study explained that after 48 weeks of open-label extension w/ B/F/TAF, 95.4% of participants maintained HIV RNA suppression & 86.6% achieved HBV DNA suppression. #CROI2025 #IDsky #MEDsky #HIVsky

www.contagionlive.com/view/allianc...

ICYMI: Dr. Moupali Das presented data at #CROI2025 showing Gilead's once-yearly Lenacapavir formulations for HIV PrEP sustain efficacy for 56 weeks. This phase 1 study paves the way for improved adherence & HIV prevention. #IDsky #HIVsky #MEDsky

Learn more: www.contagionlive.com/view/gilead-...

Top 5 HIV Stories from CROI 2025: New Treatments, HIV Remission Insights, and More Studies presented included once-yearly lenacapavir formulations for PrEP, bictegravir outperforming darunavir in advanced HIV, Immunocore's IMC-M113V showing viral control and reservoir reduction, and...

Top 5 HIV stories from #CROI2025 include new treatments, insights on #HIV remission, etc. Key updates include Gilead's once-yearly lenacapavir for PrEP, bictegravir vs darunavir in advanced HIV, & early data on Immunocore’s IMC-M113V. #IDsky #MEDsky #HIVsky

🔒: www.contagionlive.com/view/top-5-h...

This annual shot might protect against HIV infections Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Baggallini Soho Backpack - Travel Laptop Backpack for Women - Lightweight Water-Resistant Luggage Bag, Black The Soho Laptop Backpack is your new favorite work bag! With a padded laptop pocket and more than enough space for all your necessities, it will keep you effortlessly organized in style. Plus, a luggage handle sleeve makes this the perfect bag for running to make your connecting flight. This is the perfect laptop backpack, travel bag, carry on bag, work bag, school backpack and so much more.

a.co/d/7jiy4Dj

www.tumi.com/p/celina-bac...